Dambrova Gita, Kravale Zaiga, Žentiņa Dace, Krūmiņa Andra
Department of Pulmonary Diseases, Pauls Stradins Clinical University hospital, Riga, Latvia.
Riga Stradins University, Riga, Latvia.
Eur J Case Rep Intern Med. 2024 Sep 6;11(10):004840. doi: 10.12890/2024_004840. eCollection 2024.
Recurrent respiratory papillomatosis (RRP) is a chronic condition caused primarily by human papilloma virus (HPV) types 6 and 11, leading to recurrent growths in the respiratory tract. These types of papilloma can cause significant morbidity due to airway obstruction, often requiring frequent surgical interventions. Traditional treatments, including surgical removal and adjunctive therapies like antivirals and immune modulators, often fail to prevent recurrence, impacting the patient's quality of life.
This report presents a 25-year-old female with a long-standing history of RRP, diagnosed at age 2. Despite numerous interventions, including CO laser ablations, interferon therapy, HPV vaccination, and a laryngotomy with tracheal reconstruction, the patient continued to experience severe airway obstruction requiring frequent surgeries. In 2023, intravenous therapy with bevacizumab, vascular endothelial growth factor inhibitor was introduced, leading to a significant reduction in the frequency of surgical interventions from 8 to 4 per year. This reduction improved the patient's respiratory function and quality of life, highlighting bevacizumab's therapeutic potential.
The case underscores the debilitating nature of RRP and the challenges of its management. Bevacizumab, by targeting vascular endothelial growth factor (VEGF), has shown promise in reducing papilloma growth and the need for frequent surgeries. This case supports the inclusion of bevacizumab as an adjunctive therapy in RRP treatment, warranting further research to confirm its long-term efficacy and safety.
Recurrent respiratory papillomatosis is a rare and complex disease that severely impacts patients' quality of life.This case report demonstrates that bevacizumab can significantly reduce surgical interventions in recurrent respiratory papillomatosis (RRP), offering a promising treatment that improves management of this chronic condition.Bevacizumab, already used in treating various diseases by targeting VEGF, shows promise in managing RRP as well, highlighting its potential across multiple conditions and expanding its therapeutic versatility.
复发性呼吸道乳头状瘤病（RRP）是一种主要由6型和11型人乳头瘤病毒（HPV）引起的慢性疾病，可导致呼吸道反复生长乳头状瘤。这些类型的乳头状瘤可因气道阻塞而导致严重发病，常常需要频繁的手术干预。传统治疗方法，包括手术切除以及抗病毒药物和免疫调节剂等辅助治疗，往往无法预防复发，影响患者的生活质量。
本报告介绍了一名25岁女性，她自2岁起就被诊断患有RRP，病史较长。尽管进行了多次干预，包括二氧化碳激光消融、干扰素治疗、HPV疫苗接种以及喉切开术加气管重建术，但患者仍持续出现严重气道阻塞，需要频繁手术。2023年，引入了贝伐单抗（一种血管内皮生长因子抑制剂）静脉治疗，使每年的手术干预次数从8次显著减少至4次。这一减少改善了患者的呼吸功能和生活质量，凸显了贝伐单抗的治疗潜力。
该病例强调了RRP的致残性及其管理挑战。贝伐单抗通过靶向血管内皮生长因子（VEGF），在减少乳头状瘤生长和减少频繁手术需求方面显示出前景。该病例支持将贝伐单抗纳入RRP治疗的辅助治疗方法，需要进一步研究以确认其长期疗效和安全性。
复发性呼吸道乳头状瘤病是一种罕见且复杂的疾病，严重影响患者的生活质量。本病例报告表明，贝伐单抗可显著减少复发性呼吸道乳头状瘤病（RRP）的手术干预次数，提供了一种有前景的治疗方法，可改善这种慢性疾病的管理。贝伐单抗已通过靶向VEGF用于治疗多种疾病，在管理RRP方面也显示出前景，凸显了其在多种病症中的潜力，并扩展了其治疗多功能性。
